// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

The impact of depression in patients with severe asthma (SA in the Wessex Severe Asthma Cohort (WSAC

Laura Wiffen - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Asthma

N/A

Upper Respiratory Symptoms in Patients with Chronic Obstructive Pulmonary Disease

Nicolai Obling - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Application of machine learning algorithms to predict loss of asthma control: A post-hoc analysis of INCONTRO study

Sofia Necander - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Nitric oxide

The impact of obesity in patients with severe asthma in the Wessex Severe Asthma Cohort (WSAC

Lauren Fox - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Asthma

N/A

Effect of dupilumab on severe exacerbations and lung function in patients with baseline blood eosinophils =500 cells/µL

Klaus F. Rabe - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Dupilumab

Late Breaking Abstract - Corticosteroid optimisation in severe asthma using composite biomarkers to adjust dose versus a symptom/risk-based algorithm

Tim Hardman - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Nitric oxide

Late Breaking Abstract - Tackling the diagnostic challenge of COVID-19 – beyond a ‘false-negative’?

Anna Behrendt - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

Late Breaking Abstract - Randomised trial of ambulatory management of primary spontaneous pneumothorax

Rob Hallifax - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Primary spontaneous pneumothorax

N/A

Late Breaking Abstract - Two Phase 3 Randomized Clinical Trials of Gefapixant, a P2X3 Receptor Antagonist, in Refractory or Unexplained Chronic Cough (COUGH-1 and COUGH-2

Lorcan McGarvey - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Gefapixant

A new statistical diagnostic tool for respiratory diseases

Martin Wiegand - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Healthcare utilization and cost associated with chronic cough in the United Kingdom: a retrospective observational study

Surinder S. Birring - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

How do differences in the definition of good quality care affect classification of hospital performance?

Alexander Adamson - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Mass spectrometry proteomic biomarkers identify acute COPD exacerbations

Omer Elneima - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Clinical factors associated with baseline blood eosinophils among patients with asthma or COPD: NOVELTY study

Hana Müllerová - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Asthma

N/A

A qualitative study of user perspectives on electronic monitoring devices for adherence in asthma

Ireti Adejumo - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Identifying inconsistences in inpatient bronchiectasis management at a large university teaching hospital

Louise Crowley - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

First description of De Novo Inflammatory Bowel Disease (IBD in two adolescent patients after lung transplant (LTX

Doxa Kotzia - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

Infliximab

Late Breaking Abstract - Burden of pertussis in COPD: a retrospective database study in England

Emmanuel Aris - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Pertussis

N/A

Factors associated with exacerbations in patients with COPD: NOVELTY study

Hana Müllerová - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Improving Primary Ciliary Dyskinesia diagnosis using Artificial Intelligence

Andreia Lucia do Nascimento Pinto - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Primary ciliary dyskinesia

N/A

Copyright © 2026. QuantiNova All rights reserved